Bioasis Technologies Revenue and Competitors

Bioasis Technologies Inc. is a CT-based, early development-stage biopharmaceutical company focused on the non-invasive delivery of therapeutics across the blood-brain barrier (BBB) with our disruptive and enabling, best-in-class proprietary xB³ platform technology for the treatment of CNS disorders. Bioasis developing risk-mitigated, wholly-owned programs focused on CNS cancers, orphan and rare, genetic diseases with high unmet medical need where proof-of-concept exists and have the potential for fast track, early approval. Our lead programs utilize established products with proven efficacy and known safety profiles and have the potential to make these previously non-brain penetrant medicines into the new standard of care for CNS disorders. The xB³ peptide has the ability to deliver a diversity of payloads (small molecules, Abs, siRNA, enzymes and other biologics), allowing for robust testing of the platform technology without relying solely on a single modality and is highly partnerable. Bioasis continues to seek strategic relationships with leading biopharmaceutical partners and research institutions to out-license our xB³ platform technology to improve treatments across CNS / oncology space. Our focus is to deliver hope to over 1.25 billion patients worldwide who suffer from hundreds of previously untreatable diseases and disorders of the central nervous system. We know what our scientific advances can mean for patients — a second chance. Bioasis was founded in 2007 and trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.”